title: Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists.
abstract: A single randomized trial evaluated the use of intravenous cyclosporine treatment for severe attacks of ulcerative colitis. The perceived efficacy and safety of this intervention were measured through a survey of the membership of the Canadian Association of Gastroenterology (CAG).
  
  
  METHODS
  All CAG members were mailed a survey with questions regarding their familiarity with the data supporting the use of cyclosporine, their perception of the efficacy and toxicity of the drug, and whether patients who fail conventional treatment should receive this therapy. The proportion of respondents who had used cyclosporine to treat severe ulcerative colitis was determined.
  
  
  RESULTS
  One hundred and sixty-one responses were received (34% response rate). Sixty-four per cent of respondents were academic faculty members and 82% treated patients with severe colitis. Using multivariate analyses, positive associations were found between the respondents' age (P = 0.004) and subspecialty training in gastroenterology (P = 0.001), and whether respondents treat patients with severe ulcerative colitis. Twenty-six per cent of individuals had prescribed cyclosporine for this indication, of whom 88% were in academic practice (P = 0.007). Over 90% of respondents believe that further clinical trials are needed before cyclosporine becomes accepted as standard therapy.
  
  
  CONCLUSIONS
  Although the use of cyclosporine is measurable among Canadian gastroenterologists, the majority believe that further clinical trials are necessary before the drug is accepted as a standard therapy.
authors.affiliation: Department of Medicine, University of Western Ontario, London, Ontario.
authors.forename: K A
authors.initials: KA
authors.lastname: Atkinson
authors.forename: J W
authors.initials: JW
authors.lastname: McDonald
authors.forename: B
authors.initials: B
authors.lastname: Lamba
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D000328:Adult; D002170:Canada; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005762:Gastroenterology / Q000706:statistics & numerical data*; D019538:Health Care Surveys / Q000706:statistics & numerical data*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008875:Middle Aged; D012449:Safety; D012955:Societies, Medical / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine